Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First- in- human phase 1 clinical trial of BP1003 for the treatment of refractory, advanced solid tumors, including pancreatic cancer and NSCLC

Next Previous
Trial Profile

A First- in- human phase 1 clinical trial of BP1003 for the treatment of refractory, advanced solid tumors, including pancreatic cancer and NSCLC

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BP 1003 (Primary)
  • Indications Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Bio-Path Holdings

Most Recent Events

  • 08 Aug 2023 According to a Bio-Path Holdings media release, the IND application is expected to be filed for BP1003
  • 16 Aug 2022 According to a Bio-Path Holdings media release, the company expect to file an IND 2022 or the first quarter of 2023.
  • 27 Oct 2021 According to a Bio-Path Holdings media release, the company expect to file an IND for this study in 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top